Article Text

Download PDFPDF

145 The role of high-sensitivity C-reactive protein in predicting mortality beyond troponin in over 100,000 patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative CRP-risk Study)
  1. Amit Kaura1,
  2. Adam Hartley1,
  3. Vasileios Panoulas1,
  4. Ben Glampson1,
  5. Jim Davies2,
  6. Abdulrahim Mulla1,
  7. Kerrie Woods2,
  8. Joe Omigie3,
  9. Anoop D Shah4,
  10. Keith Channon2,
  11. Jonathan N Weber1,
  12. Mark R Thursz1,
  13. Paul Elliott1,
  14. Harry Hemingway4,
  15. Bryan Williams4,
  16. Folkert Asselbergs4,
  17. Michael O’Sullivan5,
  18. Dorian Haskard1,
  19. Graham Lord6,
  20. Narbeh Melikian3,
  21. Daryl Francis1,
  22. Wolfgang Koenig7,
  23. Divaka Perera8,
  24. Ajay Shah3,
  25. Rajesh Kharbanda3,
  26. Riyaz Patel4,
  27. Jamil Mayet1,
  28. Ramzi Khamis1
  1. 1NIHR Imperial College London Biomedical Research Centre and Imperial College Healthcare NHS Trust
  2. 2NIHR University of Oxford BRC and Oxford University Hospitals NHS Foundation Trust
  3. 3NIHR King’s College London BRC and King’s College Hospital NHS Foundation Trust
  4. 4NIHR University College London BRC and University College London Hospitals NHS Foundation Trust
  5. 5NIHR University of Cambridge BRC and Cambridge University Hospitals NHS Foundation Trust
  6. 6NIHR King’s College London BRC and Guy’s and St Thomas’ Hospital NHS Foundation Trust
  7. 7Deutsches Herzzentrum München, Technische Universität München and DZHK
  8. 23King’s College London


Background The incremental long-term prognostic value of high-sensitivity C-reactive protein (hsCRP) above troponin in a large real-world cohort of unselected patients presenting with suspected acute coronary syndromes (ACS) is unknown. We hypothesised that a mildly elevated hsCRP is associated with mortality risk in patients with suspected ACS, independent of troponin level.

Methods We used the National Institute for Health Research Health Informatics Collaborative data of 257,948 patients who had a troponin measured at 5 cardiac centres. We excluded patients with clinically abnormal white cell counts and hsCRP >15 mg/L to try limiting the population to those without overt infections, malignancies or systemic inflammatory conditions that may confound our analyses. Patients were divided into four hsCRP groups (<2, 2–4.9, 5–9.9 and 10–15 mg/L) and the association between hsCRP levels and all-cause mortality assessed.

Results There were 102,337 patients included in the analysis (hsCRP <2 mg/L (n=38,390), 2–4.9 mg/L (n=27,397), 5–9.9 mg/L (n=26,957) and 10–15 mg/L (n=9,593)). figure 1A displays cumulative mortality per hsCRP group, revealing increasing mortality with each consecutive group. figure 1B further stratifies the groups according to dichotomised peak troponin level as positive or negative. This shows the greatest mortality for patients in the highest hsCRP group who also had a positive troponin assay (36.0% at 3 years).

In Cox regression analysis with time-dependent covariates, even mildly raised hsCRP was an independent predictor of mortality over time, after adjusting for age, gender, haemoglobin, white cell count, platelet count, creatinine and troponin positivity. There was a positive and graded relationship between hsCRP level and mortality at baseline, which remained at 3-years (hazard ratio (95% CI) of 1.32 (1.18–1.48) for those with hsCRP 2.0–4.9mg/L, and 1.40 (1.26–1.57), and 2.00 (1.75–2.28) for those with hsCRP 5–9.9 mg/L and 10–15 mg/L, respectively.

We explored whether inclusion of hsCRP could better reclassify the population into at-risk mortality groups. The association with 30-day, 1-year and 3-year mortality was assessed using three different risk models (model 1: age, gender, haemoglobin, creatinine; model 2: model 1 plus troponin (positivity versus negativity); model 3: model 2 plus hsCRP groups. For cumulative mortality at each time point, each successive model was better able to discriminate risk than its precursor (p<0.0001); such that inclusion of troponin and hsCRP gave the most robust risk discrimination. Model 3 achieved an AUROC >0.8 at 30 days, 1-year and 3-year mortality, surpassing the use of troponin on its own.

Abstract 145 Figure 1

Kaplan-Meier mortality curve by (A) hsCRP level and (B) hsCRP level and troponin positivity

Conclusion These multi-centre, real-world data from a large cohort of patients with suspected ACS identify hsCRP as a clinically meaningful prognostic marker in addition to troponin levels and point to its potential utility in selecting patients for novel treatments targeting inflammation.

Conflict of Interest No conflicts of interest

  • acute coronary syndrome
  • C-reactive protein
  • troponin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.